PDF(Pubmed)
Abstract：
UNASSIGNED: Coronavirus disease (COVID-19) vaccines play an essential role in boosting immunity, preventing severe diseases, and alleviating the Covid-19 health crisis.
UNASSIGNED: This study aimed to explore the type and severity of short-term adverse reactions associated with BNT162 (Pfizer-BioNTech), mRNA 1273 (Moderna), and viral vector vaccines and to compare the incidence of post-vaccination Covid-19 infection among the Birzeit University community in Palestine.
UNASSIGNED: This questionnaire-based retrospective cross-sectional study was conducted among individuals who were vaccinated with at least one dose of any COVID-19 vaccine offered in Palestine during the COVID-19 pandemic. The study included participants aged 18 years and older who were vaccinated with Pfizer, Moderna, Sputnik Light, or Sputnik v.
UNASSIGNED: A total of 558 participants who were administered COVID-19 vaccine were included in the study. Sputnik (239), Pfizer vaccine recipients (236), and Moderna vaccine recipients (83). Of the viral vector vaccine recipients, 57 (23.8%) had a post-vaccination infection, compared to 30 (12.7%) for Pfizer and seven (8.4%) for Moderna. Furthermore, the reported adverse effects in the viral victor group were higher than those in the Moderna and Pfizer groups (71.7, 66.3, and 61.9%, respectively). Chills, headache, fatigue, abdominal pain, and joint pain were significantly higher in the Viral Vector vaccine group than the Moderna and Pfizer vaccine. Vomiting, tiredness, and fatigue were significantly less likely to be complained of by Pfizer vaccine recipients compared to Moderna and Viral Vector vaccine recipients (p < 0.05).
UNASSIGNED: Breakthrough infections were associated with both viral vectors and mRNA; however, the mRNA vaccine had less reported post-vaccine infection. Furthermore, the Pfizer/BioNTech COVID-19 vaccine group reported fewer commonly reported side effects (fever, chills, headache, fatigue, muscle pain, joint pain, nausea, and dizziness), followed by the Moderna and viral vector vaccines. Females and underweight participants experienced more adverse effects with both vaccines, and fewer common side effects were reported by all participants.
UNASSIGNED: This study aimed to explore the type and severity of short-term adverse reactions associated with BNT162 (Pfizer-BioNTech), mRNA 1273 (Moderna), and viral vector vaccines and to compare the incidence of post-vaccination Covid-19 infection among the Birzeit University community in Palestine.
UNASSIGNED: This questionnaire-based retrospective cross-sectional study was conducted among individuals who were vaccinated with at least one dose of any COVID-19 vaccine offered in Palestine during the COVID-19 pandemic. The study included participants aged 18 years and older who were vaccinated with Pfizer, Moderna, Sputnik Light, or Sputnik v.
UNASSIGNED: A total of 558 participants who were administered COVID-19 vaccine were included in the study. Sputnik (239), Pfizer vaccine recipients (236), and Moderna vaccine recipients (83). Of the viral vector vaccine recipients, 57 (23.8%) had a post-vaccination infection, compared to 30 (12.7%) for Pfizer and seven (8.4%) for Moderna. Furthermore, the reported adverse effects in the viral victor group were higher than those in the Moderna and Pfizer groups (71.7, 66.3, and 61.9%, respectively). Chills, headache, fatigue, abdominal pain, and joint pain were significantly higher in the Viral Vector vaccine group than the Moderna and Pfizer vaccine. Vomiting, tiredness, and fatigue were significantly less likely to be complained of by Pfizer vaccine recipients compared to Moderna and Viral Vector vaccine recipients (p < 0.05).
UNASSIGNED: Breakthrough infections were associated with both viral vectors and mRNA; however, the mRNA vaccine had less reported post-vaccine infection. Furthermore, the Pfizer/BioNTech COVID-19 vaccine group reported fewer commonly reported side effects (fever, chills, headache, fatigue, muscle pain, joint pain, nausea, and dizziness), followed by the Moderna and viral vector vaccines. Females and underweight participants experienced more adverse effects with both vaccines, and fewer common side effects were reported by all participants.
摘要：
冠状病毒病(COVID-19)疫苗在提高免疫力方面发挥着至关重要的作用，预防严重疾病，缓解新冠肺炎健康危机。
■本研究旨在探讨与BNT162（Pfizer-BioNTech）相关的短期不良反应的类型和严重程度，mRNA1273(Moderna),和病毒载体疫苗，并比较巴勒斯坦Birzeit大学社区疫苗接种后Covid-19感染的发生率。
这项基于问卷的回顾性横断面研究是在COVID-19大流行期间在巴勒斯坦接种了至少一剂任何COVID-19疫苗的个体中进行的。该研究包括18岁及以上的参与者，他们接种了辉瑞疫苗，Moderna,人造卫星光,或Sputnik诉
■总共558名接受COVID-19疫苗的参与者被纳入研究。人造卫星(239),辉瑞疫苗接种者（236），和Moderna疫苗接种者（83）。在病毒载体疫苗接受者中，57人（23.8%）有疫苗接种后感染，相比之下，辉瑞为30(12.7%)，现代为7(8.4%)。此外，病毒胜利者组报告的不良反应高于Moderna和Pfizer组（71.7、66.3和61.9％，分别)。寒冷,头痛,疲劳,腹痛,病毒载体疫苗组的关节疼痛明显高于Moderna和Pfizer疫苗。呕吐,疲倦,与Moderna和ViralVector疫苗接种者相比，辉瑞疫苗接种者抱怨疲劳的可能性明显降低（p<0.05）。
■突破性感染与病毒载体和mRNA有关；然而，mRNA疫苗的疫苗后感染报告较少.此外，辉瑞/BioNTechCOVID-19疫苗组报告的常见副作用较少(发烧，发冷,头痛,疲劳,肌肉疼痛，关节痛,恶心,和头晕)，其次是Moderna和病毒载体疫苗。女性和体重不足的参与者在两种疫苗中都有更多的不良反应，所有参与者报告的常见副作用较少。
■本研究旨在探讨与BNT162（Pfizer-BioNTech）相关的短期不良反应的类型和严重程度，mRNA1273(Moderna),和病毒载体疫苗，并比较巴勒斯坦Birzeit大学社区疫苗接种后Covid-19感染的发生率。
这项基于问卷的回顾性横断面研究是在COVID-19大流行期间在巴勒斯坦接种了至少一剂任何COVID-19疫苗的个体中进行的。该研究包括18岁及以上的参与者，他们接种了辉瑞疫苗，Moderna,人造卫星光,或Sputnik诉
■总共558名接受COVID-19疫苗的参与者被纳入研究。人造卫星(239),辉瑞疫苗接种者（236），和Moderna疫苗接种者（83）。在病毒载体疫苗接受者中，57人（23.8%）有疫苗接种后感染，相比之下，辉瑞为30(12.7%)，现代为7(8.4%)。此外，病毒胜利者组报告的不良反应高于Moderna和Pfizer组（71.7、66.3和61.9％，分别)。寒冷,头痛,疲劳,腹痛,病毒载体疫苗组的关节疼痛明显高于Moderna和Pfizer疫苗。呕吐,疲倦,与Moderna和ViralVector疫苗接种者相比，辉瑞疫苗接种者抱怨疲劳的可能性明显降低（p<0.05）。
■突破性感染与病毒载体和mRNA有关；然而，mRNA疫苗的疫苗后感染报告较少.此外，辉瑞/BioNTechCOVID-19疫苗组报告的常见副作用较少(发烧，发冷,头痛,疲劳,肌肉疼痛，关节痛,恶心,和头晕)，其次是Moderna和病毒载体疫苗。女性和体重不足的参与者在两种疫苗中都有更多的不良反应，所有参与者报告的常见副作用较少。
